CAR-T cells have shown incredible clinical potential in certain hematological malignancies but the technology faces significant challenges that limits its use. Overcoming these hurdles to expand the use of CAR-T cells has the potential to revolutionize medicine. In this video I explore the history of CAR-T and lay out the 4 major hurdles that the technology faces today.
Targeted alpha therapy is a cutting-edge form of radiopharmaceutical treatment that’s making waves in oncology. It uses alpha-emitting isotopes to deliver highly potent, localized radiation directly to cancer cells, sparing healthy tissues. With advantages over beta emitters and promising results in resistant cancers, it’s revolutionizing personalized cancer care. Let’s dive in.
Traditional cancer therapies like chemotherapy are associated with a wide array of toxicities. This is because, while the cancer cells are more sensitive than non-cancerous cells, the drugs still get into, and can kill healthy tissue. But, what if the therapy was designed in such a way that it wouldn’t become active until it was inside the tumor? This would spare healthy tissue from toxicities AND improve therapeutic efficiency.
Gene therapy has begun to mature as a therapeutic modality in medicine. But how is this technology being used to fight cancer? Join me and let’s dive into how companies like Capstan and Siren Bio are delivering genes to fight cancer.
About 85% of cancer immunotherapies, such as cancer vaccines, checkpoint inhibitors, and CAR-T cells, target T cell biology due to their potent cytotoxic abilities. However, T cell therapies often cause significant toxicities. Natural killer (NK) cells present a safer alternative but lack the expansive power of T cells, limiting their therapeutic potential. Innate Pharma has developed an NK cell engager that may overcome this limitation, unlocking NK cell therapy for cancer treatment.
Video description T cell exhaustion can severely hinder anti-cancer immune responses and several therapeutic modalities – including the most successful drug in medicine Merck’s KEYTRUDA – are designed to combat it. A paper published in Nature Immunology on November 8th our of the University of Pittsburgh describes how exhausted T
Oncoleader | Emerging Therapeutics in Oncology – Part 1 (2025) | The Foundation https://vimeo.com/1051740464?share=copy#t=0 Up Next: Gene Therapy for Cancer Launch Return to course overview Course Overview Course Instructor Jeff Martin, PhD Founder Dr. Jeff Martin is a cancer biologist with a PhD in Cancer Genetics and over a decade of
